Events  Classes  Deals  Spaces  Jobs 
    Sign in  
 
 
With Andrew Marshall (Chief Editor, Nature Biotechnology).
Friday, January 11, 2019 at 03:00 PM   Absolutely Free
New Science Building, 435 E 30th St, Rm G-19
 
     
 
 
              

        
 
Sign up for our awesome New York
Tech Events weekly email newsletter.
   
DETAILS
The talk will cover bioengineering as a concept, new approaches & applications. The aim is to cover the myriad different approaches received at a leading Nature journal. How are these biological technologies changing the face of research? And ultimately how will these technologies impact our lives: health & wellness, food security & nutrition, chemicals & materials, environment & energy. Finally, mention is made of the need for careful custodianship & oversight of new biological technologies for these approaches to be understood & embraced by society as a whole.

Andrew Marshall, PhD
BIOGRAPHY
Andrew Marshall was appointed Chief Editor ofNature Biotechnologyin 2000 when its impact factor was 11.4. He obtained a BSc with Honors & his PhD & postdoctoral experience in molecular biology & microbiology at King's College London, where he received the Helen White Prize in Microbiology. He oversees all bioengineering research at the journal, frequently speaks about biotechnology & translation at conferences, & also organizes meetings & symposia in this area. Together with his team, he focuses on identifying emerging concepts in biological technology of relevance to medicine, food/agriculture, chemicals, materials, energy & the environment. Previously, he was Editor ofCurrent Opinion in Biotechnology. He has written hundreds of articles & editorials in the trade & popular media, includingThe EconomistandPopular Science. In 2015, he was voted by Scientific American among the top 100 most influential people in biotech. He has pioneered networking events for faculty termed SciCafs in Boston, San Francisco, New York, San Diego, Houston, London & Singapore, which showcase rising stars in academia to early-stage investors & industry R&D leaders.
 
 
 
 
© 2019 GarysGuide      About   Terms   Press   Feedback